Novartis Investigative Site

Messina, ME 98158

0 studies enrolling now · 20 studies all time

What they study most

ALK-positive Non-small Cell Lung Cancer, Acromegaly, Advanced, Metastatic Breast Cancer, Asthma, Breast Cancer, Cushings Disease, Heart Failure, Heart Failure With Preserved Ejection Fraction, Hereditary Periodic Fevers, Long-term Safety of TIP, Metastatic Breast Cancer, Myelodysplastic Syndromes

Studies at this site

• A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients. — Running, not enrolling
• Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) — Running, not enrolling
• A Proof of Concept and Dose-finding Study of XXB750 in Patients With Heart Failure — Stopped early
• Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer — Completed
• Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC — Completed
• Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment. — Completed
• Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's Disease — Completed
• Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study — Completed
• Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction — Completed
• A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges — Completed
• A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi — Stopped early
• Study of Efficacy and Safety of Canakinumab in Patients With Hereditary Periodic Fevers — Completed
• Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly — Completed
• An Extension Study of the Efficacy, Safety and Tolerability of BYM338 (Bimagrumab) in Patients With Sporadic Inclusion Body Myositis Who Previously Participated in the Core Study CBYM338B2203 — Completed
• Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma — Completed
• Long-term Safety Study of QGE031 in Patients With Allergic Asthma Who Completed Study CQGE031B2201 — Stopped early
• Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM Patients — Completed
• A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation — Completed
• Ext. Long-term Safety Study in CF Patients: Single Arm TIP — Completed
• Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis — Completed